The company said the Finance Committee of its Board of Directors on December 3, 2024 authorized an increase in its ongoing share repurchase program of up to five million additional shares of common stock.

1. 01

   The company said the Finance Committee of its Board of Directors on December 3, 2024 authorized an increase in its ongoing share repurchase program of up to five million additional shares of common stock.

2. 02

   The company said the new authorization is in addition to the 1.3 million shares remaining under its share repurchase program as of December 3, 2024, under previous Board authorizations.

3. 03

   The company said repurchases may be made at management's discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions, and that the program has no specified expiration date and may be suspended or discontinued at any time.

4. 04

   IDEXX Laboratories announced the increase in its share repurchase program authorization in a press release titled "IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization" on December 9, 2024, which it attached as Exhibit 99.1.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.